Feng Biosciences
Feng Biosciences, formerly OncXerna Therapeutics, develops RNA biomarker diagnostics and matched antibody therapies for cancer.
Founded
2018Feng Biosciences, formerly OncXerna Therapeutics, develops RNA biomarker diagnostics and matched antibody therapies for cancer.
First-party archived results report that the immune score from the panel outperformed PD-L1 combined positive score in identifying patients likely to benefit from maintenance immunotherapy in HER2-negative esophagogastric adenocarcinoma. The assay is presented as a tool for prospectively driven patient selection.
The platform measures RNA-based tumor-microenvironment biology rather than a single protein marker. The company presents this multi-signal approach as a basis for stratifying patients across tumor types.
Source: web.archive.org
The licensee describes the Xerna TME Panel as an investigational assay that is not approved by the FDA, so it is not available as a cleared diagnostic. Competing tissue diagnostics, such as FoundationOne CDx, hold FDA-approved companion-diagnostic claims.
The company completed a restructuring in 2023, and its former brand website for OncXerna Therapeutics is no longer online.
Source: sec.gov
The company reaches the clinical market through exclusive licensing and companion-diagnostic agreements rather than a direct sales force. Exact Sciences licensed the laboratory services for the Xerna TME Panel for patients in the United States.
QIAGEN signed licensing and master companion-diagnostic agreements covering the Xerna platform, extending commercial access through established diagnostics partners.
Source: sec.gov
The Xerna platform reads RNA expression from a patient tumor sample to classify its dominant tumor-microenvironment biology into angiogenic and immunogenic subgroups. The Xerna TME Panel is the first clinical assay built on the platform, an investigational RNA-expression panel licensed for laboratory and companion-diagnostic development.
The company pairs the panel with therapeutic candidates to support patient selection across solid-tumor programs. It is designed to extend RNA-based biomarker measurement beyond individual cancer types.
Source: web.archive.org